POL HCQ ethics

Version vom 21. Dezember 2020, 22:32 Uhr

32279469 2020. Off-label prescribing in the midst of a pandemic: The case of hydroxychloroquine.
32238355 2020. Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence.
32294807 2020. Hydroxychloroquine use during the COVID-19 pandemic 2020.
32389025 2020. Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19.
32450097 2020. Prescription Restrictions on Hydroxychloroquine Among the Largest Florida Pharmacy Chains During the COVID-19 Pandemic: An Observational Study.
32451256 2020. COVID-19: Wait for a novel drug or act with the age old drug - Do we have a choice?
32467095 2020. Covid-19: WHO halts hydroxychloroquine trial to review links with increased mortality risk.
32471832 2020. Covid-19: Doctors criticise Indian research agency for recommending hydroxychloroquine prophylaxis.
32542496 2020. Association Between US Administration Endorsement of Hydroxychloroquine for COVID-19 and Outpatient Prescribing.
32620062 2020. Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19.
32662406 2020. Pseudoscience at the expense of rheumatic disease patients during the Coronavirus disease 2019 pandemic.
32738852 2020. Hydroxychloroquin for COVID-19 Why was so much hype?
32875045 2020. L'hydroxy-chloroquine pour traiter les patients infectes du COVID-19: quelques lecons d'an-thropologie medicale et d'histoire de la medecine.
32881845 2020. Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment - United States, January-June 2020.